Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

AbCellera Biologics (ABCL) Deferred Taxes (2021)

AbCellera Biologics' Deferred Taxes history spans 1 years, with the latest figure at $1.2 million for Q4 2021.

For the quarter ending Q4 2021, Deferred Taxes changed N/A year-over-year to $1.2 million, compared with a TTM value of -$2.0 million through Dec 2021, changed N/A, and an annual FY2023 reading of $2.0 million, up 192.72% over the prior year.
Deferred Taxes for Q4 2021 was $1.2 million at AbCellera Biologics, up from -$4.0 million in the prior quarter.
The five-year high for Deferred Taxes was $1.2 million in Q4 2021, with the low at -$4.0 million in Q3 2021.